AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20876598 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 174
Study 20876598 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 174
Study 17959585 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. acetaminophen
Number of subjects: 150
Study 17959585 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 150
Study 17959585 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 150
Study 16514325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 16514325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 16514325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 16514325 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study 16514325 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 16514325 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 0
Study 16514325 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study 16514325 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study 14588132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery/Postcard
Number of subjects: 3000
Study 14588132 — intervention group
Group type: EXPERIMENTAL
Intervention: Money/Postcard
Number of subjects: 3000
Study 14588132 — intervention group
Group type: COMPARATOR
Intervention: Postcard only
Number of subjects: 3000
Study 14588132 — intervention group
Group type: COMPARATOR
Intervention: Lottery only
Number of subjects: 3000
Study 14588132 — intervention group
Group type: COMPARATOR
Intervention: Money only
Number of subjects: 3000
Study 14588132 — intervention group
Group type: COMPARATOR
Intervention: No incentive/No postcard
Number of subjects: 3000
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 1 minute prior to propofol
Number of subjects: 120
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 2 minutes prior to propofol
Number of subjects: 120
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 4 minutes prior to propofol
Number of subjects: 120
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 6 minutes prior to propofol
Number of subjects: 120
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg administered at 10 minutes prior to propofol
Number of subjects: 120
Study 11094668 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 120
Study 11094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (any timing)
Number of subjects: 120
Study 8779456 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove and gown use
Number of subjects: 181
Study 8779456 — intervention group
Group type: COMPARATOR
Intervention: Glove use only
Number of subjects: 181
Study 8779456 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental cultures
Number of subjects: 181
Study 1416164 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 20
Study 31865288 — intervention group
Group type: EXPERIMENTAL
Intervention: Chakrayoga Meditation Program (twice a week for 2 hours during 6 weeks, consisting of 1 hour of Chakrayoga and 1 hour of meditation)
Number of subjects: 97
Study 31865288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 29079365 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow cryocompression therapy (CFCT)
Number of subjects: 125
Study 29079365 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 125
Study 25875777 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate (62 mg/kg/day, maximum dose not to exceed 6000 mg/day)
Number of subjects: 42
Study 25875777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deferoxamine mesylate)
Number of subjects: 42
Study 25087476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DENVax vaccine
Number of subjects: 96
Study 25087476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DENVax vaccine
Number of subjects: 96
Study 25087476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-dose)
Number of subjects: 96
Study 25087476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high-dose)
Number of subjects: 96
Study 22212113 — intervention group
Group type: EXPERIMENTAL
Intervention: UMI irrigated with essential oils (EOs)
Number of subjects: 45
Study 22212113 — intervention group
Group type: EXPERIMENTAL
Intervention: UMI irrigated with 0.2% chlorhexidine (CHX)
Number of subjects: 45
Study 22212113 — intervention group
Group type: COMPARATOR
Intervention: UMI irrigated with distilled water (Control)
Number of subjects: 45
Study 18775625 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Getgoing (Internet-based group counseling)
Number of subjects: 37
Study 18775625 — intervention group
Group type: COMPARATOR
Intervention: Onsite group counseling (routine)
Number of subjects: 37
Study 18633464 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent Therapy (FT)
Number of subjects: 42
Study 18633464 — intervention group
Group type: COMPARATOR
Intervention: Minimal Therapy (MT)
Number of subjects: 42
Study 18633464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MT and FT
Number of subjects: 42
Study 16198877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair with surgical correction of annular disjunction
Number of subjects: 0
Study 16198877 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve repair without surgical correction of annular disjunction
Number of subjects: 0
Study 12135015 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (12 mg/kg within 5 min, followed by a maintenance infusion of 6.7 mg/kg/h i.v.)
Number of subjects: 10
Study 12135015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10192014 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuck test
Number of subjects: 64
Study 10192014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative measurement using a Steinman pin and an adjustable caliper
Number of subjects: 64
Study 8523851 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant pulmonary tuberculosis patients continuing chemotherapy
Number of subjects: 266
Study 8523851 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously untreated pulmonary tuberculosis patients
Number of subjects: 266
Study 8523851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with drug-resistant tuberculosis
Number of subjects: 266
Study 8523851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with drug-resistant pulmonary tuberculosis
Number of subjects: 266
Study 2407098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with counseling to achieve changes in calorie, sodium, and/or potassium intake.
Number of subjects: 0
Study 2407098 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated assessments of diet based on participant recording.
Number of subjects: 0
Study 6779371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (600‐1200 mg daily)
Number of subjects: 21
Study 6779371 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin (1.6 g daily)
Number of subjects: 21
Study 30003988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Number of subjects: 0
Study 30003988 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied once daily for 4 weeks
Number of subjects: 0
Study 27297740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=155)
Number of subjects: 301
Study 27297740 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=146)
Number of subjects: 301
Study 25881461 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnaojing Injection (20 mL per day for 14 days), followed by Chinese medical granules for 21 days, and Naoxueshu Oral Liquid (10 mL, 3 times per day till 3 months)
Number of subjects: 228
Study 25881461 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment of Western internal medicine
Number of subjects: 228
Study 25881461 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 228
Study 23740822 — intervention group
Group type: EXPERIMENTAL
Intervention: Online audit and feedback (group A)
Number of subjects: 258
Study 23740822 — intervention group
Group type: COMPARATOR
Intervention: No feedback (group B)
Number of subjects: 258
Study 20826553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 20826553 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 811
Study 19729890 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus oral cholecalciferol (150,000 IU once a month for the first 2 months, followed by 90,000 IU once a month for the last 4 months)
Number of subjects: 56
Study 19729890 — intervention group
Group type: COMPARATOR
Intervention: Calcium plus monthly placebo
Number of subjects: 56
Study 18031640 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite teaching (model/video teaching)
Number of subjects: 10
Study 18031640 — intervention group
Group type: COMPARATOR
Intervention: Cadaver-based teaching
Number of subjects: 10
Study 18031640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both teaching methods
Number of subjects: 10
Study 14717748 — intervention group
Group type: EXPERIMENTAL
Intervention: D(LO2)2C (estimated pulmonary diffusing capacity for O2 during exercise)
Number of subjects: 11
Study 14717748 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined analytical procedure for estimating D(LO2)
Number of subjects: 11
Study 11718495 — intervention group
Group type: COMPARATOR
Intervention: Cycloserine 500 mg after a 12-hour fast (reference)
Number of subjects: 12
Study 11718495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with a high-fat meal
Number of subjects: 12
Study 11718495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with orange juice
Number of subjects: 12
Study 11718495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine 500 mg with antacids
Number of subjects: 12
Study 9429006 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive advertising message
Number of subjects: 15
Study 9429006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral advertising message
Number of subjects: 15
Study 9429006 — intervention group
Group type: COMPARATOR
Intervention: Warning advertising message
Number of subjects: 15
Study 9429006 — intervention group
Group type: COMPARATOR
Intervention: Bare platform
Number of subjects: 15
Study 8239101 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/10 mL) administered at 10 mL/min for ten minutes, with up to 3 mg of open-label flumazenil if no response.
Number of subjects: 170
Study 8239101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL/min) administered for ten minutes.
Number of subjects: 170
Study 3631792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients with previous test results displayed
Number of subjects: 4683
Study 3631792 — intervention group
Group type: COMPARATOR
Intervention: Control patients without previous test results displayed
Number of subjects: 4683
Study 29352722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucuna pruriens (MP) powder
Number of subjects: 14
Study 29352722 — intervention group
Group type: COMPARATOR
Intervention: Marketed levodopa/carbidopa (LD/CD)
Number of subjects: 14
Study 27446616 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 20 min after acquisition (EX90)
Number of subjects: 48
Study 27446616 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 1 h after acquisition (EX90+1)
Number of subjects: 48
Study 27446616 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise (90% Maximal Power Output) at 2 h after acquisition (EX90+2)
Number of subjects: 48
Study 27446616 — intervention group
Group type: COMPARATOR
Intervention: Control group (rested) (CON)
Number of subjects: 48
Study 25686147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insertion
Number of subjects: 63
Study 25686147 — intervention group
Group type: COMPARATOR
Intervention: Nasal insertion
Number of subjects: 63
Study 23661528 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement containing forskolin, rutin, and vitamins B1 and B2 for 30 days
Number of subjects: 38
Study 23661528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21034946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal purse string suture around the internal inguinal ring (IIR) using 2 needle holders
Number of subjects: 150
Study 21034946 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal knotting using a Reverdin needle (RN)
Number of subjects: 150
Study 18579283 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative preparation (G1)
Number of subjects: 32
Study 18579283 — intervention group
Group type: COMPARATOR
Intervention: Modified preparation with cavosurface bevel (G2)
Number of subjects: 32
Study 18579283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 32
Study 16636486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (10 mg/kg bolus followed by infusion of 0.15 mg . kg(‐1) . min (‐1) until total dose reached 12.5 mg)
Number of subjects: 217
Study 16636486 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard PCI)
Number of subjects: 217
Study 12006956 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (1.5 mmol/kg per day)
Number of subjects: 152
Study 12006956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 10692751 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 122
Study 10692751 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 122
Study 10692751 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 122
Study 10692751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 7473451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/d of conjugated equine estrogen (CEE) cyclically (n = 15)
Number of subjects: 90
Study 7473451 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/d of transdermal estradiol (E2) cyclically (n = 17)
Number of subjects: 90
Study 7473451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/d of CEE continuously (n = 17)
Number of subjects: 90
Study 7473451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of CEE and 2.5 mg/d of MPA continuously (n = 19)
Number of subjects: 90
Study 7473451 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group (n = 22)
Number of subjects: 90
Study 1685182 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasoduodenal feeding (from the first postoperative day)
Number of subjects: 24
Study 1685182 — intervention group
Group type: COMPARATOR
Intervention: Control group (feeding started on the fourth postoperative day)
Number of subjects: 24
Study 1685182 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasoduodenal feeding
Number of subjects: 24
Study 1685182 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 6315329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily for two weeks)
Number of subjects: 7
Study 6315329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (4 X 10 mg daily for four weeks)
Number of subjects: 7
Study 6315329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily for two weeks)
Number of subjects: 7
Study 6315329 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine alone (4 X 10 mg daily)
Number of subjects: 7
Study 31626571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-adapted first-line treatment (radiotherapy alone, chemotherapy alone, or combined-modality approaches)
Number of subjects: 471
Study 30275228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel followed by paclitaxel, cisplatin, and S‐1 (PCS) chemotherapy
Number of subjects: 17
Study 27484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased femoral offset
Number of subjects: 359
Study 27484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and acetabular offset
Number of subjects: 359
Study 27484875 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased acetabular offset
Number of subjects: 359
Study 25549086 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (three daily doses)
Number of subjects: 267
Study 25549086 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (six doses over 3 days)
Number of subjects: 267
Study 22332205 — intervention group
Group type: EXPERIMENTAL
Intervention: High ω‐3 intake (≥0.20 g/d)
Number of subjects: 357
Study 22332205 — intervention group
Group type: COMPARATOR
Intervention: Low ω‐3 intake (<0.20 g/d)
Number of subjects: 357
Study 19996989 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (Sex Hormones and Physical Exercise study)
Number of subjects: 0
Study 19996989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18713761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg
Number of subjects: 110
Study 18713761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15972582 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly oral ibandronate 150 mg
Number of subjects: 144
Study 15972582 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly oral ibandronate 100 mg
Number of subjects: 144
Study 15972582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 12929899 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH classroom component
Number of subjects: 0
Study 12929899 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH food service component
Number of subjects: 0
Study 12929899 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH physical education (PE) component
Number of subjects: 0
Study 10720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-insulin-hypoglycemic condition (insulin infusion at 1.5 mU/min x kg)
Number of subjects: 30
Study 10720074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-insulin-hypoglycemic condition (insulin infusion at 15.0 mU/min x kg)
Number of subjects: 30
Study 10720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-insulin-euglycemic condition (insulin infusion at 1.5 mU/min x kg)
Number of subjects: 30
Study 10720074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-insulin-euglycemic condition (insulin infusion at 15.0 mU/min x kg)
Number of subjects: 30
Study 8784650 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 21
Study 1611649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg QD
Number of subjects: 217
Study 1611649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg QD
Number of subjects: 217
Study 1611649 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg QD
Number of subjects: 217
Study 6140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol and testosterone implants
Number of subjects: 55
Study 6140343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30561059 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 2 mg/kg q24 PO
Number of subjects: 285
Study 30561059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 30195826 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered decision aid (DA)
Number of subjects: 98
Study 30195826 — intervention group
Group type: COMPARATOR
Intervention: Standard education (SE)
Number of subjects: 98
Study 26582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise (15-20 RM)
Number of subjects: 21
Study 26582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load resistance exercise (10-12 RM)
Number of subjects: 21
Study 26582633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance exercise (6-8 RM)
Number of subjects: 21
Study 24862255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (800mg/day)
Number of subjects: 130
Study 24862255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22856192 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-associated recombinant SEF21
Number of subjects: 0
Study 20099352 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide-enhanced MRA (0.1 mmol/kg)
Number of subjects: 395
Study 18191732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg weekly until ferritin >500 ng/ml, 200 mg monthly thereafter)
Number of subjects: 35
Study 16393724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beta2-agonist
Number of subjects: 333
Study 16393724 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 333
Study 16393724 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-MRET (three-minute respiratory exercise test)
Number of subjects: 333
Study 16393724 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 333
Study 12860899 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-on (n=25)
Number of subjects: 50
Study 12860899 — intervention group
Group type: COMPARATOR
Intervention: CRT-off (n=25)
Number of subjects: 50
Study 12860899 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-on
Number of subjects: 50
Study 12860899 — intervention group
Group type: COMPARATOR
Intervention: CRT-off
Number of subjects: 50
Study 9869598 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5-20 mg/kg)
Number of subjects: 13
Study 9869598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8703705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium loading test
Number of subjects: 120